Ng John, Zhang Chi, Gidea-Addeo Daniela, Saif Muhammad Wasif
Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital, New York, NY 10032, USA.
JOP. 2012 Mar 10;13(2):155-8.
Pancreatic cancer, the 4th leading cause of cancer death in the U.S., remains a challenging disease for the oncology community. Less than 20% of all cases are potentially cured by surgical resection, while the large majority of cases are deemed either unresectable or metastatic upon diagnosis. Advances in treating locally advanced pancreatic cancer have been few and modest. In this year's American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, three abstracts (#252, #254, #313) were presented with novel approaches towards treating locally advanced pancreatic cancer. Surgery for recurrent disease, a promising new chemoradiation regimen, and the application of an exciting multi-agent regimen (FOLFIRINOX: oxaliplatin, irinotecan, leucovorin, 5-fluorouracil) in a non-clinical trial setting, highlight the novel approaches focused on the management of this difficult disease.
胰腺癌是美国癌症死亡的第四大主要原因，对肿瘤学界来说仍然是一种具有挑战性的疾病。所有病例中不到20%可通过手术切除得到潜在治愈，而绝大多数病例在诊断时被认为无法切除或已转移。局部晚期胰腺癌的治疗进展很少且不显著。在今年的美国临床肿瘤学会（ASCO）胃肠道癌症研讨会上，有三篇摘要（#252、#254、#313）介绍了治疗局部晚期胰腺癌的新方法。复发性疾病的手术、一种有前景的新放化疗方案，以及在非临床试验环境中应用一种令人振奋的多药联合方案（FOLFIRINOX：奥沙利铂、伊立替康、亚叶酸、5-氟尿嘧啶），突出了针对这种难治性疾病管理的新方法。
